You are here

New Fluticasone Furoate/Vilanterol Combo Drug Submitted for FDA Review

GSK and Theravance seek an indication for FF/VI (100/25 mcg) for the long-term once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations.

GSK and Theravance are reviewing the strategy for a future U.S. filing for asthma.

FF/VI is one of several respiratory medicines being developed by GSK. Other potential products include the investigational LAMA/LABA combination umeclidinium bromide (UMEC)/VI, VI monotherapy, and MABA (GSK961081), all developed in collaboration with Theravance. GSK is also developing FF monotherapy, UMEC monotherapy, and an anti-IL5 monoclonal antibody (mepolizumab).

Read the news release from GlaxoSmithKline.

Recent Headlines

More research is needed to confirm the finding
Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention
A new 'road map' might make it easier
Rationing, canceled treatments, and fearful patients